Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Molecular mechanisms in leukemogenesis].

Kinuko Mitani1

  • 1Dept. of Hematology, Dokkyo University School of Medicine.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Darbepoetin alfa for the treatment of anemia in myelodysplastic syndromes: a post-marketing surveillance study in Japan.

International journal of hematology·2026
Same author

NUP98 rearrangements in adult AML patients: evaluation of clinical implications and identification of novel fusion partners.

Leukemia·2026
Same author

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.

Blood advances·2025
Same author

Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.

British journal of haematology·2025
Same author

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.

Annals of hematology·2025
Same author

HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells.

Leukemia research·2025

Mutations in signal transduction pathways, including tyrosine kinases and transcription factors, drive leukemia development. These genetic alterations in key cellular regulators contribute to hematopoietic cell neoplastic transformation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Hematology

Background:

  • Leukemia development involves mutations in signal transduction molecules regulating cell differentiation and proliferation.
  • Aberrant receptor tyrosine kinases (e.g., FLT3, c-Kit) and cytoplasmic tyrosine kinases (e.g., BCR/ABL) are implicated in various leukemias and tumors.
  • RAS GTP-binding protein mutations and chromosomal translocations affecting transcription factors are common in hematopoietic malignancies.

Purpose of the Study:

  • To review the role of mutations in signal transduction pathways in the neoplastic transformation of hematopoietic cells.
  • To highlight specific examples of genetic alterations in tyrosine kinases, RAS proteins, and transcription factors involved in leukemia.

Main Methods:

  • Literature review and analysis of genetic mutations in key signaling molecules.

Related Experiment Videos

  • Examination of chromosomal translocations and their resulting chimeric proteins in specific leukemia subtypes.
  • Discussion of mutations in tumor suppressor genes affecting cell cycle regulation.

    • Main Results:

    • Mutations in FLT3, c-Kit, and BCR/ABL are critical in myeloid and lymphoid leukemias.
    • Chromosomal translocations create oncogenic fusion proteins like AML1/MTG8, TEL/AML1, and PML/RAR alpha, driving leukemogenesis.
    • Mutations in RAS pathway proteins and tumor suppressors (p53, RB, p16) also contribute to hematopoietic cancers.

    Conclusions:

    • Genetic alterations at various levels of signal transduction pathways are fundamental to leukemia pathogenesis.
    • Understanding these molecular defects provides insights into the mechanisms of neoplastic transformation in hematopoietic cells.